Physician profile
Thomas A Barnard
NPI 1487654117
$7,425.93
in general payments reported to CMS, 2019-2025
16 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $459 · 2021: $1,056 · 2022: $1,030 · 2023: $2,334 · 2024: $959 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,607 · Acquisitions: $1,663 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,607.08 |
| Acquisitions | $1,662.90 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $2,792.40 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $1,021.87 | 2019-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $835.86 | 2019-2024 | Yutiq, Iluvien |
| Genentech USA, INC. | $731.24 | 2019-2025 | Vabysmo, Lucentis |
| Apellis Pharmaceuticals, INC. | $508.12 | 2022-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $283.00 | 2025 | Yutiq, Iluvien, Purified Cortrophin Gel |
| Abbvie INC. | $246.17 | 2022-2025 | Ozurdex |
| Astellas Pharma US INC | $239.88 | 2023-2025 | Izervay |
| Allergan, INC. | $221.61 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $149.33 | 2023-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $145.00 | 2019-2021 | |
| Eyepoint US, INC. | $100.23 | 2020-2023 | |
| Coherus Oncology, INC. | $63.74 | 2023 | |
| Harrow Eye, LLC | $50.67 | 2024 | Triesence, Iheezo |
| Sandoz INC. | $22.30 | 2024 | Cimerli |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $14.51 | 2024 | Xipere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,742.66 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Barnard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.